
Recurrent and Metastatic Breast Cancer: Symptoms, Tests and Treatment — 2026 Update
Recurrent breast cancer is cancer that returns after treatment has been completed. It may come back locally (in the breast, chest wall or regional lymph nodes) or spread to other organs such as bone, lung, liver or brain. Local recurrence can still be treated with the aim of cure, and although metastatic disease is usually not curable, many patients now control it for years with drugs chosen according to the cancer type. At Namarak Hospital, our multidisciplinary team plans treatment according to the latest 2026 NCCN and ESMO guidelines.
How and when does breast cancer come back?
Even after complete surgery and treatment, a very small number of cancer cells may remain and grow again later. The timing differs by type.
TNBC and HER2-positive: usually within the first 2–5 years; after 5 years the risk falls considerably
HR+/HER2−: can return early or even after 5–10 years, so completing endocrine therapy and long-term follow-up are important
The risk is higher with large tumors, many positive lymph nodes, or residual cancer after treatment before surgery
Symptoms that should prompt a visit to the doctor
A new lump in the breast, chest wall, surgical scar, armpit or above the collarbone
Redness, skin thickening or a non-healing sore on the chest wall
Persistent bone pain, especially at night, or back pain that does not improve
Persistent cough or shortness of breath
Upper right abdominal discomfort, yellowing of the eyes, or unexplained weight loss
Severe headache, vomiting, weakness of the arms or legs, or seizures
These symptoms can have other causes, but you should see your doctor rather than waiting for the next scheduled appointment.
Follow-up after treatment
Standard follow-up consists of history and physical examination every 3–6 months at first, then less often, with a yearly mammogram. Routine whole-body scans or blood tumor markers in people without symptoms do not prolong survival and are not recommended. ctDNA testing for residual cancer is still a research tool.
When recurrence is suspected — what tests are done?
A biopsy to confirm — very important to rule out other conditions and to re-test ER, PR and HER2, which may have changed and can change the treatment
Whole-body imaging, such as CT, bone scan or PET/CT, to check for spread elsewhere
Biomarker testing in metastatic disease, such as ESR1, PIK3CA, BRCA, PD-L1 and HER2-low status, to choose drugs that match the cancer
Germline BRCA testing from blood, if not done before
Local recurrence (locoregional recurrence) — cure is still possible
After breast-conserving surgery: usually mastectomy with assessment of the lymph nodes; selected patients may have repeat breast-conserving surgery with re-irradiation
After mastectomy (chest wall): surgical removal with clear margins, and radiation if that area has not been treated before
Regional lymph nodes: surgery and/or radiation
Additional treatment after surgery: according to cancer type, such as endocrine therapy for HR+ disease, HER2-targeted therapy for HER2-positive disease, and consideration of chemotherapy for ER-negative disease
Metastatic breast cancer — principles of treatment
The main treatment is systemic therapy chosen by cancer type and biomarkers. The goal is to control the disease for as long as possible with good quality of life, changing to the next line of treatment when the disease progresses.
HR+/HER2−: endocrine therapy + CDK4/6 inhibitor first line, ESR1 monitoring, then biomarker-matched drugs such as camizestrant, elacestrant, capivasertib, gedatolisib and ADCs — see HR+/HER2−
HER2-positive: THP followed by maintenance (± palbociclib or tucatinib), or T-DXd + pertuzumab — see HER2-positive
TNBC: immunotherapy with chemotherapy or sacituzumab for PD-L1-positive disease, or Dato-DXd / sacituzumab when immunotherapy cannot be used — see TNBC
HER2-low / ultralow: T-DXd as an additional option — see HER2-low
Inherited BRCA mutation: PARP inhibitors (olaparib, talazoparib)
Surgery or radiation to metastatic sites
Some patients have only a few sites of spread (oligometastasis). The NRG-BR002 trial, published in the Journal of Clinical Oncology in October 2026, found that adding stereotactic radiation (SBRT) or surgery to all metastases alongside first-line drugs did not improve progression-free or overall survival, so it is not recommended routinely. It still has a role in relieving symptoms such as bone pain, spinal cord compression or brain lesions.
Bone metastases
The most common site; bone-strengthening drugs (zoledronic acid or denosumab) reduce fractures and pain
Short-course radiation relieves pain effectively; some patients need surgical bone fixation
A dental check is advised before starting bone-strengthening drugs
Brain metastases
Local treatment with stereotactic radiosurgery (SRS) or surgery, together with drugs that reach the brain, such as T-DXd or tucatinib-containing regimens in HER2-positive disease
Routine brain imaging is not recommended without symptoms, but may be considered when the result would change treatment
Palliative care and quality of life
Palliative care does not mean stopping treatment. It is provided alongside cancer treatment from early in metastatic disease to control pain, fatigue and nausea, support the patient and family emotionally, and plan care ahead, improving quality of life throughout treatment. Joining a clinical trial is also an option worth discussing with your doctor.
Important note: some new drugs are approved in the US or Europe but may not yet be registered or reimbursable in Thailand. Our team will explain the options that are actually available and the estimated costs.
Frequently asked questions (FAQ)
Can recurrent breast cancer be cured?
If it returns locally, such as in the breast, chest wall or regional lymph nodes, there is still a chance of cure with surgery, radiation and drugs. If it has spread to other organs, it is usually not curable but can be controlled for many years.
Why is another biopsy needed when cancer comes back?
To confirm that it is cancer and to re-test ER, PR and HER2, because the cancer type may have changed, which changes the choice of drugs.
Should I have whole-body scans every year after treatment?
Not if you have no symptoms, because routine scans or blood tumor markers do not prolong survival. Standard follow-up is physical examination and a yearly mammogram, and seeing your doctor promptly if symptoms appear.
If there are only a few sites of spread, can they be treated with radiation or surgery?
Yes, to relieve symptoms, but the recent NRG-BR002 trial found that treating every site with radiation or surgery alongside drugs did not prolong survival. Your doctor will consider this individually.
Does palliative care mean stopping treatment?
No. It is care for symptoms and quality of life alongside cancer treatment, and starting early helps patients and families cope better.
About Namarak Hospital
Namarak Hospital is a specialized breast hospital in Bangkok, where breast surgeons, medical oncologists, radiologists and pathologists plan treatment together as a multidisciplinary team according to the latest international guidelines. To discuss your situation or request a second opinion, see Breast Cancer Treatment, Second Opinion, or contact us on LINE, tel. +66 2 059 0245.
Related treatment guides
References
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026
de Azambuja E, et al. Metastatic breast cancer: ESMO Clinical Practice Guideline. Ann Oncol 2026
Chmura SJ, et al. NRG-BR002: Metastasis-directed therapy for oligometastatic breast cancer. J Clin Oncol, October 2026
ASCO Breast Cancer Follow-Up and Management After Primary Treatment Guideline
Medically reviewed by: Namarak Hospital medical team · Guidelines checked: 16 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments